Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30772669 | 0.79 | ALDH1A1 (0.50) | HTTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL25568628 | 0.79 | HTT (0.62) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL25568226 | 0.78 | CPB1 (0.46) | HTTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL21997088 | 0.77 | HTT (0.55) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL3940773 | 0.76 | LMNA (0.56) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL3940775 | 0.76 | LMNA (0.56) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL18254066 | 0.75 | HTT (0.81) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL9874334 | 0.74 | HTT (0.79) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL15346534 | 0.74 | HTT (0.79) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL9340146 | 0.74 | HTT (0.79) | HTTLMNASMN1; SMN2KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313374-B1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-05-02 | — | — | US | disclosed |
| US-8399482-B2 | 6-substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| US-20110190339-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| EP-2313374-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | Sanofi-Aventis (FR) | 2011-04-27 | — | — | EP | disclosed |
| WO-2009156099-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190339-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | MYLK2, MYLK, MYLK3 | HTT 3169/4885LMNA 1291/4885SMN1; SMN2 936/4885 |
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | MYLK2, MYLK, MYLK3 | HTT 2901/4885LMNA 1392/4885SMN1; SMN2 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.